Epigenetic enhancement of adoptive T cell immunotherapy

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-03-10 DOI:10.1016/j.ccell.2025.02.022

Zhenyu Dai, Melody Smith

引用次数: 0

Abstract

Isshiki et al. and Porazzi et al. report that inhibiting enhancer of zeste homolog 1 (EZH1) and EZH2 enhances chimeric antigen receptor (CAR)/T cell receptor (TCR)-based therapies by reprogramming tumors to be more immunogenic and improving T cell phenotype and demonstrate the efficacy of this combination in preclinical models across hematologic and solid cancers. Clinical trials are ongoing to evaluate its safety and therapeutic potential.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.